Liraglutide
Liraglutide is a GLP-1 receptor agonist marketed under brand names including Victoza and Saxenda.
- Editorial attention
- Emerging
- Tracked this week
- 0
- Sources this week
- 0
- Last activity
- Sep 21, 2026
Signal strength reflects editorial attention across tracked sources — not medical certainty or strength of evidence.
- Pending editorial review
A system check is an automated check of the official sources, not a human review. An editorial review is recorded only when one of our editors has reviewed the page.
Liraglutide at a glance
- About this topic
- Liraglutide is a GLP-1 receptor agonist marketed under brand names including Victoza and Saxenda.
- Current status
- No editor-reviewed status summary yet. The official records below update automatically.
- Last updated
- Primary sources
- Latest official record: Drug shortage update: Liraglutide Injection — Current (opens the source in a new tab) (U.S. Food and Drug Administration (Drug Shortages), Sep 21, 2026)
- Key facts from tracked records
- 20 clinical trials tracked from ClinicalTrials.gov
What’s the latest on Liraglutide?
0 totalNo briefings on this topic yet. Official records and trials below are updated continuously.
What do the official records show?
Primary sources and peer-reviewed research- Drug shortage update: Liraglutide Injection — Current (opens the source in a new tab)
Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-13). Company: Novo Nordisk, Inc.. Estimated shortage duration: TBD
- Drug shortage update: Liraglutide Injection — Current (opens the source in a new tab)
Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12). Company: Novo Nordisk, Inc.. Estimated shortage duration: TBD
- Drug shortage update: Liraglutide Injection — Current (opens the source in a new tab)
Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-22). Company: Novo Nordisk, Inc.. Distributed by Teva
- Drug shortage update: Liraglutide Injection — Current (opens the source in a new tab)
Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15). Company: Novo Nordisk, Inc.. Product will be available until discontinuation in January 2027
- Drug shortage update: Liraglutide Injection — Current (opens the source in a new tab)
Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-20). Company: Novo Nordisk, Inc.. Distributed by Teva
- Drug shortage update: Liraglutide Injection — Current (opens the source in a new tab)
Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-03). Company: Hikma Pharmaceuticals USA, Inc.
- Drug shortage update: Liraglutide Injection — Current (opens the source in a new tab)
Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-02). Company: Hikma Pharmaceuticals USA, Inc.
- Drug shortage update: Liraglutide Injection — Current (opens the source in a new tab)
Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-85). Company: Meitheal Pharmaceuticals, Inc.
Which clinical trials are being tracked?
All trials- TOLEDDO: Effect of Weekly GLP1 Agonist Treatment in "Double Diabetes"
Centre Hospitalier Universitaire Dijon. Conditions: Double Diabetes. Investigational — not approved for the use studied.
- INFLAM MOTION: A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis
4Moving Biotech. Conditions: Knee Osteoarthritis; Synovitis of Knee. Investigational — not approved for the use studied.
- The Evira Study: Additional Support During Obesity Treatment
Karolinska Institutet. Conditions: Childhood Obesity; Treatment Adherence. Investigational — not approved for the use studied.
- This Randomized Trial Aims to Investigate the Efficacy of Balanced Nutritional Tablets-Comprehensive Multivitamin and Mineral Supplements- in Preventing Micronutrient Deficiencies Among Patients Utilizing GLP-1 RAs for Weight Loss in Comparison to a Placebo Control
General Committee of Teaching Hospitals and Institutes, Egypt. Conditions: Micronutrient Deficiencies. Investigational — not approved for the use studied.
- GLIDE-HF: GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry
Miedziowe Centrum Zdrowia SA. Conditions: Heart Failure With Preserved Ejection Fraction; Obesity; Diastolic Heart Failure; Pulmonary Hypertension; Iron Defici…. Investigational — not approved for the use studied.
- Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome
Beni-Suef University. Conditions: Polycystic Ovary. Investigational — not approved for the use studied.